

ROMO TO M1 IN A YEAR: SOUTH WEST LONDON DESP

AUTHORS: Bartholomew Entire, Screener/Grader
CONTENT ADVISER: Farhan Zaidi, Clinical Lead
DATA PROVIDER: Andrea Orosz-Ruszin, Programme Manager

2 year recall of persons with diabetes who had ROMO grade results on two occasions may still develop maculopathy

I observed a pattern of patients who did not have retinopathy on an appointment one to two years before the screening where suspected maculopathy (M1) was detected.


A two-year interval screening will result in some patients not having maculopathy detected earlier.

SUPPORTING DATA

Out of 16926 patients who were ROMO in 2021 and in 2022, 67 had M1 results in 2023.


All 67 patients had type 2 diabetes.

RESULTS OF 67 PATIENTS



- M1 on at least one occasion
- M1 on more than one occasion
- M1 confirmed at HES

43 HES & M1 ON MORE THAN ONE OCCASION



- Diet
- Tablets
- Insulin
- Combination

Example: Patient 66 YEARS OLD / TYPE 2 / ON INSULIN / DIABETIC SINCE 1998

DATE	CARE	RE	LE
April 2018	RDS	ROMO	ROMO
April 2019	RDS	ROMO	ROMO
March 2021	RDS	ROMO	ROMO
March 2022	RDS	ROMO	ROMO
November 2023	RDS	R1M1	R2M1
January 2024	HES	R2M1	R2M1

CONCLUSION

For a proportion of RDS patients with ROMO gradings on two previous screenings, M1 maculopathy had developed just one year later.

With the move to two-yearly ROMO screening, patients should be advised that if they experience symptoms of maculopathy between screening visits, they should see an optician.

Symptoms include difficulty with daily tasks such as reading, watching TV or reading signs when driving due to blurring/distortion of central vision as a result of damage to the macula.